National Cohort Study of Idiopathic and Heritable Pulmonary Arterial Hypertension (NAIAD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01907295|
Recruitment Status : Recruiting
First Posted : July 24, 2013
Last Update Posted : May 20, 2022
Pulmonary arterial hypertension (PAH), or high blood pressure in the lungs, is a rare condition that can shorten life. Although the cause of this disease is usually unknown, in about 70% of heritable and 15-20% of idiopathic cases there is a change in a gene (a mutation) that controls how blood vessels grow and function. The gene is called bone morphogenetic protein type receptor 2 (BMPR2). Although mutations in BMPR2 are a risk factor for PAH, not everyone with a mutation gets the disease. Additional genetic and environmental factors are likely to contribute. The investigators suspect that mutations in other genes are responsible for some cases of PAH. In this study the investigators aim to recruit all patients with PAH and some of their relatives and follow them up for several years. The investigators hope to discover new mutations for this disease and to determine what factors lead to poor outcome, and to understand what triggers disease in patients with mutations.
Who can participate? Adults with PAH, their relatives and controls (one off blood sample)
|Condition or disease|
|Pulmonary Arterial Hypertension|
What does the study involve?
PAH patients will be seen at their local centre by their service team but they will have additional bloods taken. Relatives of PAH patients will be seen every year at their nearest PAH centre. Tests will include:
- Epidemiology Questionnaire to assess factors affecting health
- An echocardiogram (ECHO) to assess the size, shape, pumping action and the extent of any damage to the heart.
- Lung function tests which include blowing measurements to assess gas volumes within the lungs as well as assessment of how the lungs exchange gases.
- Optional right heart catheterisation (RHC) to determine how much blood your heart is pumping while you are resting and on exercise. Optional Cardiac Magnetic Resonance tests. To measure heart function. ( to be done only once)
- 6 minute walk test. To measure exercise capacity
- Cardiopulmonary exercise test. A bicycle exercise test, which will indicate how much blood your heart pumps while resting and with different levels of exercise.
- Electrocardiogram (ECG), a test that measures the electrical activity of the heart
- Blood tests
Controls:Blood sample and medical data collected once
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||3600 participants|
|Target Follow-Up Duration:||3 Years|
|Official Title:||National Cohort Study of Idiopathic and Heritable Pulmonary Arterial Hypertension|
|Actual Study Start Date :||February 2014|
|Estimated Primary Completion Date :||December 2022|
|Estimated Study Completion Date :||December 2022|
Patients diagnosed with idiopathic, anorexigen-induced, heritable PAH and PVOD/PCH
Relatives and controls
Relative has a family member diagnosed with idiopathic, anorexigen-induced, heritable PAH and PVOD/PCH Self declared healthy individuals
- To recruit a national cohort (1000 subjects) of heritable, idiopathic PAH and PVOD/PCH cases. [ Time Frame: 8 years ]The purpose of this study is to set up a national cohort of heritable, idiopathic PAH cases, PVOD/PCH and their relatives, to study the genetic and environmental contributions to disease. Setting up of this cohort of patients and relatives will provide the best resource for understanding what causes or triggers the disease, how to predict risk of death and response to therapy in individual patients, and to provide new ways of preventing and treating pulmonary arterial hypertension. The study will enable a better understanding for the first time the natural history of PAH, whether inherited or not. National outcomes to be measured will include survival, progression of the disease, changes in 6 minute walk distance, admissions to hospital for PAH and cause of death. Incidence of new cases of PAH will be measured in relatives as well.
- To recruit PAH patients (1000) and family members to a Biorepository for serum/plasma and urine to identify biomarkers of disease onset, progression and response to treatment. [ Time Frame: 8 years ]To establish a Biorepository for serum/plasma, urine, tissues and cells from heritable pulmonary arterial hypertension (HPAH) patients, PVOD/PCH and their relatives, and patients with idiopathic PAH. This will allow studies to identify novel biomarkers of disease onset, progression and response to individual or combination therapies.
- longitudinal clinical evaluation and sampling of HPAH family members [ Time Frame: 8 years ]To characterise the natural history of disease onset and progression in the UK national cohort of PAH patients, coupled with longitudinal clinical evaluation and sampling of heritable pulmonary arterial hypertension family members. Longitudinal clinical data will be collated on subjects including haemodynamic data, clinical and research bloods, echocardiographic data, 6 minute walk distance, cardiopulmonary exercise testing, nt-proBNP and safety data ( admissions to hospital PAH related and cause and date of death) and medications.
- Elucidation of the underlying genetic architecture of idiopathic and heritable PAH [ Time Frame: 8 years ]1000 subjects will have a one off blood sample taken for next generation genetic sequencing (up to their entire genome). Samples will be sequenced to identify novel genetic mutations associated with PAH. A single blood sample will also be taken for mutation testing for BMPR2 and other genes associated with PAH. Outcomes will include identification of novel mutations in PAH
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01907295
|Contact: Nicholas Morrell||01223 firstname.lastname@example.org|
|Contact: Carmen Treacy||1223 email@example.com|
|Royal United Hospitals Bath||Recruiting|
|Bath, United Kingdom, BA1 3NG|
|Contact: Robert MacKenenzie Ross, PI|
|Royal Papworth Hospital NHS Trust||Recruiting|
|Cambridge, United Kingdom|
|Principal Investigator: Joanna Pepke-Zaba|
|Golden Jubilee National Hospital||Recruiting|
|Glasgow, United Kingdom|
|Principal Investigator: Colin Church|
|London, United Kingdom|
|Principal Investigator: Martin Wilkins|
|Royal Brompton Hospital||Recruiting|
|London, United Kingdom|
|Principal Investigator: S. John Wort|
|Royal Free Hospital||Recruiting|
|London, United Kingdom|
|Principal Investigator: Gerry Goglan|
|Newcastle, United Kingdom|
|Principal Investigator: James Lordan|
|Sheffield, United Kingdom|
|Principal Investigator: David Kiely|
|Principal Investigator:||Nicholas Morrell||University of Cambridge|